Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone

Nathan Gossai; Megan V. Hilgers; Lynda E. Polgreen; Emily G. Greengard

doi:10.1002/pbc.25393

Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone

Nathan Gossai, Megan V. Hilgers, Lynda E. Polgreen, Emily G. Greengard

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

We report a 14 year-old female with Giant Cell Tumor of Bone, successfully treated with denosumab, who developed critical hypercalcemia after completion of therapy. Five months after her last denosumab treatment, serum calcium rose to 16.5mg/dL (normal 8.7-10.8mg/dL), nearly double her prior level of 8.4mg/dL while receiving denosumab. She required emergent intervention to treat her hypercalcemia, which was attributed to rebound osteoclast activity and osteopetrotic bone. Denosumab is widely used in adults and increasingly in pediatric oncology populations and our experience demonstrates the need for close monitoring for electrolyte derangements following discontinuation. Pediatr Blood Cancer 2015;62:1078-1080.

Original language	English (US)
Pages (from-to)	1078-1080
Number of pages	3
Journal	Pediatric Blood and Cancer
Volume	62
Issue number	6
DOIs	https://doi.org/10.1002/pbc.25393
State	Published - Jun 1 2015

Bibliographical note

Publisher Copyright:
© 2015 Wiley Periodicals, Inc.

Keywords

Denosumab
Giant cell tumor of bone
Hypercalcemia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1002/pbc.25393

OpenUrl availability

Full text

Cite this

@article{c879febb6b2e4ad09fc7832a56a5ab52,

title = "Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone",

abstract = "We report a 14 year-old female with Giant Cell Tumor of Bone, successfully treated with denosumab, who developed critical hypercalcemia after completion of therapy. Five months after her last denosumab treatment, serum calcium rose to 16.5mg/dL (normal 8.7-10.8mg/dL), nearly double her prior level of 8.4mg/dL while receiving denosumab. She required emergent intervention to treat her hypercalcemia, which was attributed to rebound osteoclast activity and osteopetrotic bone. Denosumab is widely used in adults and increasingly in pediatric oncology populations and our experience demonstrates the need for close monitoring for electrolyte derangements following discontinuation. Pediatr Blood Cancer 2015;62:1078-1080.",

keywords = "Denosumab, Giant cell tumor of bone, Hypercalcemia",

author = "Nathan Gossai and Hilgers, {Megan V.} and Polgreen, {Lynda E.} and Greengard, {Emily G.}",

note = "Publisher Copyright: {\textcopyright} 2015 Wiley Periodicals, Inc.",

year = "2015",

month = jun,

day = "1",

doi = "10.1002/pbc.25393",

language = "English (US)",

volume = "62",

pages = "1078--1080",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone

AU - Gossai, Nathan

AU - Hilgers, Megan V.

AU - Polgreen, Lynda E.

AU - Greengard, Emily G.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - We report a 14 year-old female with Giant Cell Tumor of Bone, successfully treated with denosumab, who developed critical hypercalcemia after completion of therapy. Five months after her last denosumab treatment, serum calcium rose to 16.5mg/dL (normal 8.7-10.8mg/dL), nearly double her prior level of 8.4mg/dL while receiving denosumab. She required emergent intervention to treat her hypercalcemia, which was attributed to rebound osteoclast activity and osteopetrotic bone. Denosumab is widely used in adults and increasingly in pediatric oncology populations and our experience demonstrates the need for close monitoring for electrolyte derangements following discontinuation. Pediatr Blood Cancer 2015;62:1078-1080.

AB - We report a 14 year-old female with Giant Cell Tumor of Bone, successfully treated with denosumab, who developed critical hypercalcemia after completion of therapy. Five months after her last denosumab treatment, serum calcium rose to 16.5mg/dL (normal 8.7-10.8mg/dL), nearly double her prior level of 8.4mg/dL while receiving denosumab. She required emergent intervention to treat her hypercalcemia, which was attributed to rebound osteoclast activity and osteopetrotic bone. Denosumab is widely used in adults and increasingly in pediatric oncology populations and our experience demonstrates the need for close monitoring for electrolyte derangements following discontinuation. Pediatr Blood Cancer 2015;62:1078-1080.

KW - Denosumab

KW - Giant cell tumor of bone

KW - Hypercalcemia

UR - http://www.scopus.com/inward/record.url?scp=84927792230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927792230&partnerID=8YFLogxK

U2 - 10.1002/pbc.25393

DO - 10.1002/pbc.25393

M3 - Article

C2 - 25556556

AN - SCOPUS:84927792230

SN - 1545-5009

VL - 62

SP - 1078

EP - 1080

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 6

ER -

Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this